search
Back to results

Left Ventricular Synchronous Versus Sequential MultiSpot Pacing for Cardiac Resynchronization Therapy (CRT) (SYNSEQ)

Primary Purpose

Heart Failure

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Electrophysiological Study
Sponsored by
Medtronic Cardiac Rhythm and Heart Failure
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject is indicated or recommended for CRT-P or CRT-D device according to current applicable ESC/AHA guidelines
  • Subject is in sinus rhythm
  • Subject receives optimal heart failure oral medical therapy
  • Subject is willing to sign the informed consent form
  • Subject is 18 years or older

Exclusion Criteria:

  • Subject has permanent atrial fibrillation/flutter or tachycardia
  • Subject has pure right bundle branch block (= no additional left ventricular conduction delays)
  • Subject has left bundle branch block and QRS-duration of > 150 ms and no sign of myocardial scar indicated by late gadolinium enhancement MRI
  • Subject experienced recent myocardial infarction, within 40 days prior to enrollment
  • Subject underwent valve surgery, within 90 days prior to enrollment
  • Subject is post heart transplantation, or is actively listed on the transplantation list
  • Subject is implanted with a left ventricular assist device
  • Subject has severe renal disease (up to physicians discretion)
  • Subject is on continuous or uninterrupted infusion (inotropic) therapy for heart failure (≥ 2 stable infusions per week)
  • Subject has severe aortic stenosis (with a valve area of <1.0 cm2 or significant valve disease expected to be operated within study period)
  • Subject has complex and uncorrected congenital heart disease
  • Subject has a mechanical heart valve
  • Pregnant or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth control
  • Subject is enrolled in another study that could confound the results of this study, without documented pre-approval from Medtronic study manager

Sites / Locations

  • Klinika Choroby Wieńcowej
  • Medical University of Silesia, Silesian Center for Heart Disease,
  • Národný ústav srdcových a cievnych chorôb, a.s. (NUSCH)
  • Východoslovenský ústav srdcových a cievnych chorôb, a.s. (VUSCH)
  • Hospital Universitari I Politècnic La Fe
  • Skåne University Hospital
  • Queen Elizabeth Medical Centre

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Electrophysiological Study

Arm Description

Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.

Outcomes

Primary Outcome Measures

Percentage Change in Positive Left Ventricular dP/dt Max (mmHG/Sec)
LV dP/dt max is a measurement of the initial velocity of myocardial contraction and is derivative of the LV-pressure. The percentage changes correspond to a percentage change between a pacing configuration (pacing on, e.g., Multispot pacing) and baseline (LV pacing off). There are several repetitions of pacing off and on for each pacing configuration. For one repetition, the percentage change is determined as ([median dP/dt max during pacing On] - (median baseline dP/dt max during pacing Off])/[median dP/dt max during pacing Off]. From all percentage changes for a given pacing configuration and subject, a regression analysis is performed to determine the regression predicted highest percentage change. The presented percentage change is the average over all subjects.

Secondary Outcome Measures

Correlation Between Percentage Change LV dP/dt Max and Percentage Change Blood Pressure
Measured by invasive arterial blood line connected to a sensitive membrane displacement sensor. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were collected.The percentage changes correspond to a percentage change between a pacing configuration (pacing on, e.g., Multispot pacing) and baseline (LV pacing off). There are several repetitions of pacing off and on for each pacing configuration. For one repetition, the percentage change is determined as ([median pressure during pacing On] - (median pressure during pacing Off])/[median pressure during pacing Off]. Correlation will be summarized over all pacing configurations and time points since the interest is in the overall correlation between LV dP/dt max and other measurements, not in the correlation per pacing configuration or per time point. The general linear model as described in Blank & Altman, Biometrical Journal 310 (1995), p 446, was used to determine the correlation.
Correlation Between Percentage Change LV dP/dt Max and Percentage Change Non-Invasive Blood Pressure
Acquired through finger volume clamp
Correlation Between Percentage Change LV dP/dt Max and Q-LV Ratio
Derived from intra-cardiac leads (invasive) and surface electrodes (non-invasive) respectively. The Q-LV interval is defined as the time from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV electrogram (EGM) during a cardiac cycle. The Q-LV ratio will be calculated as Q-LV/QRS duration. Correlation will be summarized over all pacing configurations since the interest is in the overall correlation between LV dP/dt max and other measurements, not in the correlation per pacing configuration. The general linear model as described in Blank & Altman, Biometrical Journal 310 (1995), p 446, was used to determine the correlation between % change LV dP/dt max and Q-LV ratio.
Correlation Between Percentage Change LV dP/dt Max and % Change QRS Width
Derived from surface electrodes (non-invasive). The percentage change is determined as ([QRS width during pacing On] - (QRS width during pacing Off])/[QRS width during pacing Off]. The correlation between % change LV dP/dt max and % change QRS width will be summarized over all pacing configurations since the interest is in the overall correlation between LV dP/dt max and other measurements, not in the correlation per pacing configuration or per time point. The general linear model as described in Blank & Altman, Biometrical Journal 310 (1995), p 446, was used to determine the correlation.

Full Information

First Posted
June 8, 2016
Last Updated
September 3, 2020
Sponsor
Medtronic Cardiac Rhythm and Heart Failure
search

1. Study Identification

Unique Protocol Identification Number
NCT02914457
Brief Title
Left Ventricular Synchronous Versus Sequential MultiSpot Pacing for Cardiac Resynchronization Therapy (CRT)
Acronym
SYNSEQ
Official Title
Left Ventricular Synchronous Versus Sequential MultiSpot Pacing for CRT
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
November 7, 2016 (Actual)
Primary Completion Date
April 20, 2018 (Actual)
Study Completion Date
April 20, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Cardiac Rhythm and Heart Failure

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The SYNSEQ study intends to assess the positive left ventricular dP/dt max achieved by MultiSpot LV pacing (either simultaneously or sequentially) in comparison to the response achieved by the current (standard) BiV pacing configuration in patients indicated/recommended for cardiac resynchronization therapy.
Detailed Description
The following pacing configurations will be evaluated. Biventricular pacing (BiV): Pacing will be performed on one LV electrode pair, (at 3 different longitudinal locations), and on the tip of the RV-lead. In total, three different pacing BiV settings will be evaluated. Configuration 1: RV + LV lateral Apex, Configuration 2: RV + LV lateral Mid, Configuration 3: RV + LV lateral Base (Reference: Standard CRT) MultiSpot simultaneous LV-ventricular pacing (MultiSpot-SYN): Pacing will be performed on 3 electrodes on the LV wall, placed at different longitudinal locations, and on the tip of the RV-lead simultaneously. Configuration 4: RV + LV lateral Apex + LV lateral Mid + LV lateral Base MultiSpot sequential LV-ventricular pacing (MultiSpot-SEQ): 3 electrodes on the LV wall will be paced sequentially. The RV electrode will be paced simultaneously with last paced LV electrode.The timing-sequence and the amount of spots will depend on the electrical delays measured during the experiments. Configuration 5: LV lateral Apex => LV lateral Mid => LV lateral Base + RV

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Electrophysiological Study
Arm Type
Experimental
Arm Description
Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
Intervention Type
Procedure
Intervention Name(s)
Electrophysiological Study
Intervention Description
Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
Primary Outcome Measure Information:
Title
Percentage Change in Positive Left Ventricular dP/dt Max (mmHG/Sec)
Description
LV dP/dt max is a measurement of the initial velocity of myocardial contraction and is derivative of the LV-pressure. The percentage changes correspond to a percentage change between a pacing configuration (pacing on, e.g., Multispot pacing) and baseline (LV pacing off). There are several repetitions of pacing off and on for each pacing configuration. For one repetition, the percentage change is determined as ([median dP/dt max during pacing On] - (median baseline dP/dt max during pacing Off])/[median dP/dt max during pacing Off]. From all percentage changes for a given pacing configuration and subject, a regression analysis is performed to determine the regression predicted highest percentage change. The presented percentage change is the average over all subjects.
Time Frame
Participants were followed for the time of the EP procedure, which had a median duration of 48 min
Secondary Outcome Measure Information:
Title
Correlation Between Percentage Change LV dP/dt Max and Percentage Change Blood Pressure
Description
Measured by invasive arterial blood line connected to a sensitive membrane displacement sensor. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were collected.The percentage changes correspond to a percentage change between a pacing configuration (pacing on, e.g., Multispot pacing) and baseline (LV pacing off). There are several repetitions of pacing off and on for each pacing configuration. For one repetition, the percentage change is determined as ([median pressure during pacing On] - (median pressure during pacing Off])/[median pressure during pacing Off]. Correlation will be summarized over all pacing configurations and time points since the interest is in the overall correlation between LV dP/dt max and other measurements, not in the correlation per pacing configuration or per time point. The general linear model as described in Blank & Altman, Biometrical Journal 310 (1995), p 446, was used to determine the correlation.
Time Frame
Participants were followed for the time of the EP procedure, which had a median duration of 48 min
Title
Correlation Between Percentage Change LV dP/dt Max and Percentage Change Non-Invasive Blood Pressure
Description
Acquired through finger volume clamp
Time Frame
Participants were followed for the time of the EP procedure, which had a median duration of 48 min
Title
Correlation Between Percentage Change LV dP/dt Max and Q-LV Ratio
Description
Derived from intra-cardiac leads (invasive) and surface electrodes (non-invasive) respectively. The Q-LV interval is defined as the time from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV electrogram (EGM) during a cardiac cycle. The Q-LV ratio will be calculated as Q-LV/QRS duration. Correlation will be summarized over all pacing configurations since the interest is in the overall correlation between LV dP/dt max and other measurements, not in the correlation per pacing configuration. The general linear model as described in Blank & Altman, Biometrical Journal 310 (1995), p 446, was used to determine the correlation between % change LV dP/dt max and Q-LV ratio.
Time Frame
Participants were followed for the time of the EP procedure, which had a median duration of 48 min
Title
Correlation Between Percentage Change LV dP/dt Max and % Change QRS Width
Description
Derived from surface electrodes (non-invasive). The percentage change is determined as ([QRS width during pacing On] - (QRS width during pacing Off])/[QRS width during pacing Off]. The correlation between % change LV dP/dt max and % change QRS width will be summarized over all pacing configurations since the interest is in the overall correlation between LV dP/dt max and other measurements, not in the correlation per pacing configuration or per time point. The general linear model as described in Blank & Altman, Biometrical Journal 310 (1995), p 446, was used to determine the correlation.
Time Frame
Participants were followed for the time of the EP procedure, which had a median duration of 48 min

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is indicated or recommended for CRT-P or CRT-D device according to current applicable ESC/AHA guidelines Subject is in sinus rhythm Subject receives optimal heart failure oral medical therapy Subject is willing to sign the informed consent form Subject is 18 years or older Exclusion Criteria: Subject has permanent atrial fibrillation/flutter or tachycardia Subject has pure right bundle branch block (= no additional left ventricular conduction delays) Subject has left bundle branch block and QRS-duration of > 150 ms and no sign of myocardial scar indicated by late gadolinium enhancement MRI Subject experienced recent myocardial infarction, within 40 days prior to enrollment Subject underwent valve surgery, within 90 days prior to enrollment Subject is post heart transplantation, or is actively listed on the transplantation list Subject is implanted with a left ventricular assist device Subject has severe renal disease (up to physicians discretion) Subject is on continuous or uninterrupted infusion (inotropic) therapy for heart failure (≥ 2 stable infusions per week) Subject has severe aortic stenosis (with a valve area of <1.0 cm2 or significant valve disease expected to be operated within study period) Subject has complex and uncorrected congenital heart disease Subject has a mechanical heart valve Pregnant or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth control Subject is enrolled in another study that could confound the results of this study, without documented pre-approval from Medtronic study manager
Facility Information:
Facility Name
Klinika Choroby Wieńcowej
City
Warszawa
Country
Poland
Facility Name
Medical University of Silesia, Silesian Center for Heart Disease,
City
Zabrze
Country
Poland
Facility Name
Národný ústav srdcových a cievnych chorôb, a.s. (NUSCH)
City
Bratislava
Country
Slovakia
Facility Name
Východoslovenský ústav srdcových a cievnych chorôb, a.s. (VUSCH)
City
Košice
Country
Slovakia
Facility Name
Hospital Universitari I Politècnic La Fe
City
València
Country
Spain
Facility Name
Skåne University Hospital
City
Lund
Country
Sweden
Facility Name
Queen Elizabeth Medical Centre
City
London
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
35647062
Citation
Sterlinski M, Zakrzewska-Koperska J, Maciag A, Sokal A, Osca-Asensi J, Wang L, Spyropoulou V, Maus B, Lemme F, Okafor O, Stegemann B, Cornelussen R, Leyva F. Acute Hemodynamic Effects of Simultaneous and Sequential Multi-Point Pacing in Heart Failure Patients With an Expected Higher Rate of Sub-response to Cardiac Resynchronization Therapy: Results of Multicenter SYNSEQ Study. Front Cardiovasc Med. 2022 May 12;9:901267. doi: 10.3389/fcvm.2022.901267. eCollection 2022.
Results Reference
derived

Learn more about this trial

Left Ventricular Synchronous Versus Sequential MultiSpot Pacing for Cardiac Resynchronization Therapy (CRT)

We'll reach out to this number within 24 hrs